INTRODUCTION: @entity101 guidelines recommend fixed-dose combinations for enhanced blood pressure (BP) reduction and compliance. The objective of this study was to assess the effectiveness and safety of fixed-dose @entity4687 / @entity3591 combination in reducing and controlling BP in Greek @entity101 @entity1 , as well as the effect of baseline BP and added cardiovascular risk on BP reduction. METHODS: This 6-month prospective observational study included male or female @entity1    18 years with essential @entity101 prescribed fixed-dose combination @entity4687 / @entity3591 . BP was measured at baseline and 3 and 6 months. Baseline cardiovascular risk and treatment compliance were also assessed. RESULTS: In 2231 per protocol @entity1 , mean systolic BP decreased from 157.0  15.4 mm Hg to 129.0  7.9 mm Hg after 6 months, and diastolic BP from 91.5  10.1 to 78.8  6.7 mm Hg (both p < 0.001). BP control was achieved in 84.8% at 6 months. @entity1 with higher baseline added cardiovascular risk or BP had greater BP reduction (p < 0.001). Compliance was good (97.1% took treatment "every day" or "quite often") and few (n = 27; 1.2%) discontinued treatment prematurely due to adverse events. CONCLUSIONS: Fixed-dose @entity4687 / @entity3591 safely and effectively reduced high BP in real-life practice, achieving BP control in most @entity1 . About half of Greek @entity101 @entity1 have high/very high added cardiovascular risk.

Blood pressure reduction and control with fixed-dose combination XXXX / @entity3591 : A Pan-Hellenic prospective observational study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive', 'Hypertension'] @entity4687 :: ('MESH:D020913', 'Chemical') :: ['perindopril']
@entity4687 :: (MESH:D020913,Chemical) :: ['perindopril']
